NPHLA Daily
NPHLA Daily
Tuesday, November 10, 2026 · 4-minute read
Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.
Top development today
What changed today in Metabolic: 5 trial updates, 3 new studies
NPHLA tracked 8 new official records on this desk today: 5 trial updates, 3 new studies. First: New trial registered: Ocular Changes in Patients Using Tirzepatide or Semaglutide
Metabolic signal
Results posted on ClinicalTrials.gov: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without…
Phase 2, Eli Lilly and Company. Conditions: Overweight or Obesity; CKD; Type 2 Diabetes. Interventions: Retatrutide; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
Regulatory signal
What changed today in Regulatory: 2 safety alerts, 1 recall record
NPHLA tracked 3 new official records on this desk today: 1 recall record, 2 safety alerts. First: Recall: Eugia US LLC (f/k/a Auro Medics Pharma LLC) Issues Voluntary Nationwide Recall of Vancomycin Hydrochloride for Injection USP… — reason given: not stated (firm: not stated).
Aesthetics & Longevity signal
What changed today in Aesthetics & Longevity: 1 trial update, 1 new study
NPHLA tracked 2 new official records on this desk today: 1 trial update, 1 new study. First: Trial status changed to “Recruiting”: Efficacy and Safety of Two Hair Supplements in Men With Androgenic Alopecia
One thing worth watching
Comments close: Compounding Animal Drugs From Bulk Drug Substances: Compounding Under CGMP in Federally-Registered Facilities; Draft Guidance for Industry; Availability; Agency Information…
November 26, 2026 — verified from the Federal Register comments_close_on.
5 things to know
- What changed today in Metabolic: 5 trial updates, 3 new studies
- What changed today in Regulatory: 2 safety alerts, 1 recall record
- What changed today in Aesthetics & Longevity: 1 trial update, 1 new study
- Trial status changed to “Recruiting”: Efficacy and Safety of Two Hair Supplements in Men With Androgenic Alopecia (ClinicalTrials.gov (U.S. National Library of Medicine))
- Results posted on ClinicalTrials.gov: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2… (ClinicalTrials.gov (U.S.…
Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.